Beyond KRAS: Practical Molecular Targets in Pancreatic Adenocarcinoma.
BRAF
KRAS
Pancreatic adenocarcinoma
RET
Targeted therapy
Journal
Case reports in oncology
ISSN: 1662-6575
Titre abrégé: Case Rep Oncol
Pays: Switzerland
ID NLM: 101517601
Informations de publication
Date de publication:
Historique:
received:
04
12
2018
accepted:
04
12
2018
entrez:
23
2
2019
pubmed:
23
2
2019
medline:
23
2
2019
Statut:
epublish
Résumé
Pancreatic adenocarcinoma (PDAC) has a grim prognosis. Molecular and genomic analyses revealed that the striking majority of these tumors are driven by KRAS mutation, currently not amenable to targeted therapy. However, other driver mutations were found in a small fraction of patients. Herein we report of 3 cases of patients with metastatic PDAC and wildtype KRAS, found to harbor BRAF or RET pathogenic alterations. The patients were treated with targeted therapies with variable success. In our opinion, those proof-of-concept cases argue in favor of additional research and clinical trials' effort in this small but significant PDAC population with uncommon driver mutations.
Identifiants
pubmed: 30792639
doi: 10.1159/000496018
pii: cro-0012-0007
pmc: PMC6381925
doi:
Types de publication
Case Reports
Langues
eng
Pagination
7-13Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Références
Zhonghua Wai Ke Za Zhi. 2011 Sep 1;49(9):771-3
pubmed: 22177426
Nat Rev Cancer. 2014 Mar;14(3):173-86
pubmed: 24561444
N Engl J Med. 2015 Jan 1;372(1):30-9
pubmed: 25399551
N Engl J Med. 2014 Nov 20;371(21):2030-1
pubmed: 25409376
N Engl J Med. 2015 Aug 20;373(8):726-36
pubmed: 26287849
J Clin Oncol. 2015 Dec 1;33(34):4023-31
pubmed: 26392102
Mol Cancer Ther. 2016 Apr;15(4):533-47
pubmed: 27009213
Nat Rev Dis Primers. 2016 Apr 21;2:16022
pubmed: 27158978
Sci Rep. 2016 Oct 20;6:35848
pubmed: 27762323
Lancet Oncol. 2017 Apr;18(4):486-499
pubmed: 28259610
Cancer Discov. 2017 Aug;7(8):818-831
pubmed: 28572459
Cancer Cell. 2017 Aug 14;32(2):185-203.e13
pubmed: 28810144
Science. 2017 Sep 15;357(6356):1156-1160
pubmed: 28912244
Lancet Oncol. 2017 Oct;18(10):1307-1316
pubmed: 28919011
Nat Rev Clin Oncol. 2018 Mar;15(3):151-167
pubmed: 29134959
Nucleic Acids Res. 2018 Jan 4;46(D1):D1062-D1067
pubmed: 29165669
J Clin Oncol. 2018 Feb 20;36(6):536-542
pubmed: 29320312
Cancer Biol Ther. 2018 Aug 3;19(8):645-648
pubmed: 29565707